135 related articles for article (PubMed ID: 37405915)
41. Identification of somatic mutations in the von Hippel-Lindau (VHL) gene in a patient with renal cell carcinoma.
Wang WC; Chen HJ; Tseng YH; Lai YC
J Formos Med Assoc; 2009 Nov; 108(11):886-93. PubMed ID: 19933033
[TBL] [Abstract][Full Text] [Related]
42. Natural history of Von Hippel-Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study.
Wang J; Zhang L; Qiu J; Li Z; Wu Y; Zhang C; Yao L; Gong K; Li X; Zhou L
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2631-2641. PubMed ID: 34709473
[TBL] [Abstract][Full Text] [Related]
43. Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice.
Harlander S; Schönenberger D; Toussaint NC; Prummer M; Catalano A; Brandt L; Moch H; Wild PJ; Frew IJ
Nat Med; 2017 Jul; 23(7):869-877. PubMed ID: 28553932
[TBL] [Abstract][Full Text] [Related]
44. [Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer].
Mikhaĭlenko DS; Grigor'eva MV; Rusakov IG; Kurynin RV; Popov AM; Peters MV; Matveev VB; Iakovlev ES; Nosov DA; Liubchenko LN; Tiuliandin SA; Strel'nikov VV; Zaletaev DV
Mol Biol (Mosk); 2012; 46(1):71-81. PubMed ID: 22642103
[TBL] [Abstract][Full Text] [Related]
45. Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma.
Williamson SR; Zhang S; Eble JN; Grignon DJ; Martignoni G; Brunelli M; Wang M; Gobbo S; Baldridge LA; Cheng L
Am J Surg Pathol; 2013 Aug; 37(8):1131-9. PubMed ID: 23648463
[TBL] [Abstract][Full Text] [Related]
46. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
47. Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome--clinicopathological features and comparative genomic analysis of 3 cases.
Rao P; Monzon F; Jonasch E; Matin SF; Tamboli P
Hum Pathol; 2014 Sep; 45(9):1966-72. PubMed ID: 25081542
[TBL] [Abstract][Full Text] [Related]
48. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
49. Intratumoral heterogeneity in kidney cancer.
Ricketts CJ; Linehan WM
Nat Genet; 2014 Mar; 46(3):214-5. PubMed ID: 24569233
[TBL] [Abstract][Full Text] [Related]
50. Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.
German P; Bai S; Liu XD; Sun M; Zhou L; Kalra S; Zhang X; Minelli R; Scott KL; Mills GB; Jonasch E; Ding Z
Oncogene; 2016 Sep; 35(38):4973-80. PubMed ID: 26973240
[TBL] [Abstract][Full Text] [Related]
51. Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma.
Hamano K; Esumi M; Igarashi H; Chino K; Mochida J; ISHIDA And H; Okada K
J Urol; 2002 Feb; 167(2 Pt 1):713-7. PubMed ID: 11792959
[TBL] [Abstract][Full Text] [Related]
52. Novel and recurrent germline mutations in the VHL gene in 5 Arab patients with Von Hippel-Lindau disease.
Faiyaz-Ul-Haque M; Jamil M; Aslam M; Abalkhail H; Al-Dayel F; Basit S; Nawaz Z; Zaidi SHE
Cancer Genet; 2020 May; 243():1-6. PubMed ID: 32179488
[TBL] [Abstract][Full Text] [Related]
53. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.
Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD
Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082
[TBL] [Abstract][Full Text] [Related]
54. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract][Full Text] [Related]
55. A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.
Cingoz S; van der Luijt RB; Kurt E; Apaydin M; Akkol I; Ozgen MH
Fam Cancer; 2013 Mar; 12(1):111-7. PubMed ID: 23224817
[TBL] [Abstract][Full Text] [Related]
56. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
57. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
58. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
59. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
60. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
